SHARE

Endonovo Therapeutics Inc (OTCMKTS:ENDV) was a notable outperformer during Tuesday’s trading session, surging by 40% on heavy volumes, which were 20 times the 30 day average turnover. Endonovo has been in a strong uptrend over the last couple of trading sessions indicative of follow up buying, which is considered to be a bullish sign. The stock currently trades above all daily moving averages. The oscillator measuring momentum is showing first signs of a reversal. The RSI oscillator continues to surge higher pointing towards the strong bullish momentum. Traders see the stock retesting support at levels of $1.10 in the near term.

ENDV

Endonovo Therapeutics Inc (OTCMKTS:ENDV) has started working on a next generation cell therapy that can be used to treat chronic and acute graft-versus-host diseases. As per the reports, Endonovo looks forward to using ex vivo enhanced stem cells extracted from the human umbilical cord and Cytotronics to develop this therapy.

Management Call

The senior management team of the company is delighted to make this announcement and hopes that it will help the company touch newer heights in the coming years. According to Dr. Donnie Rudd, Chief Scientist, Endonovo, there’s an immense need for immune privileged stem cells to treat various chronic diseases.

Until now Endonovo kept taking the help of human umbilical cord to develop them, but the enhanced demand has prompted the company to shift its focus to Cytotronics platform. It is capable of helping Endonovo come up with high-quality, optimized immuno-regulatory stem cells that can be used as off-the-shelf, allogeneic therapy in the Graft-Versus-Host Diseases’ treatment.

Available reports claim that Graft-Versus-Host Disease is a very common issue that may happen after allogeneic tissue transplants, such as cord-blood and bone marrow transplants. Under this disease, immune cells available in the transplanted tissue start recognizing the host recipient as a foreign recipient and begin to eat its cells. Acute GVHD can lead to severe damage to skin, liver, gastrointestinal tract, mucosa, etc.

If one pays a close heed to all the major hematopoietic stem cell transplants around the world, he can notice that the probability of occurrence of acute GVHD lies between 20%-80%.

Nowadays mesenchymal stem cells, due to their therapeutic nature and ability to be cultivated and harvested quickly, are captivating researchers from all over the world. These stem cells are being deployed in different treatments focused upon inflammatory diseases, and can also be used to treat acute GVHD.

Endonovo has confidence in their potential and hopes that they will start a new revolution in the healthcare industry in the near future.

LEAVE A REPLY